DSM Biomedical is teaming up with Cerapedics to create the next-generation peptide enhanced bone graft, according to newswiretoday.com.
Here are five things to know:
1. Cerapedics will offer its proprietary synthetic small peptide, P-15, technology and DSM will provide its regenerative materials portfolio.
2. DSM has a bioceramic platform featuring a carbonated apatite matrix.
3. Cerapedics' P-15 technology promotes bone growth from cell attraction to attachment to activation.
4. Cerapedics' i-FACTOR Peptide Enhanced Bone Graft has been on the U.S. market since 2008. i-FACTOR was approved for anterior cervical discectomy and fusion in 2015.
5. The next-generation technology will focus on the lumbar spine.